血液测试称为 DELFI（早期拦截片段的 DNA 评估），可检测脱落到血液中的癌细胞 DNA 中的片段变化，称为无细胞 DNA (cfDNA)。在最近的一项研究中，研究人员使用 DELFI 技术对从美国、欧盟 (E.U.) 和香港的 724 个人采集的血浆样本进行检测，以检测肝细胞癌 (HCC)，一种肝癌。
DELFI 技术通过研究基因组不同区域循环中存在的无细胞 DNA 的大小和数量，使用血液测试来测量 DNA 在细胞核内的包装方式。健康细胞将 DNA 包装成一个井井有条的手提箱，基因组的不同区域被小心地放置在不同的隔间中。相比之下，癌细胞的细胞核就像更加杂乱无章的手提箱，来自整个基因组的物品随意地扔在里面。当癌细胞死亡时，它们会以混乱的方式将 DNA 片段释放到血液中。
DELFI 通过检查数百万个 cfDNA 片段的异常模式（包括不同基因组区域中 DNA 的大小和数量）来识别癌症的存在。研究人员说，DELFI 方法只需要低覆盖率测序，使这项技术在筛选环境中具有成本效益。
该研究得到了 Miriam 博士和 Sheldon G. Adelson 医学研究基金会、Stand Up to Cancer-Dutch Cancer Society International Translational Cancer Research Dream Team Grant (SU2C-AACR-DT1415)、格雷基金会、英联邦基金会、SU2C 的支持INTIME 肺癌拦截梦之队补助金、马克癌症研究基金会、Delfi Diagnostics 的研究补助金、美国国立卫生研究院补助金 CA121113、CA006973、CA233259、GM136577、CA237624 和 CA062924，以及国防部 CDMRP 奖 W81XWH-20- 1-0605。 Stand Up to Cancer 是美国癌症研究协会管理的娱乐产业基金会的一项计划。
News Release 18-Nov-2022
Novel AI blood test detects liver cancer
Peer-Reviewed Publication
Johns Hopkins Medicine
**EMBARGOED TILL 11:30 A.M. ET FRIDAY, NOV. 18**
A novel artificial intelligence blood testing technology developed and used by Johns Hopkins Kimmel Cancer Center researchers to successfully detect lung cancer in a 2021 study has now detected more than 80% of liver cancers in a new study of 724 people.
The blood test, called DELFI (DNA evaluation of fragments for early interception) detects fragmentation changes among DNA from cancer cells shed into the bloodstream, known as cell-free DNA (cfDNA). In the most recent study, investigators used the DELFI technology on blood plasma samples obtained from 724 individuals in the U.S., the European Union (E.U.) and Hong Kong to detect hepatocellular cancer (HCC), a type of liver cancer.
The researchers believe this is the first genome-wide fragmentation analysis independently validated in two high-risk populations and across different racial and ethnic groups with different causes associated with their liver cancers.
Their findings were reported Nov. 18 in Cancer Discovery and at the American Association for Cancer Research Special Conference: Precision Prevention, Early Detection, and Interception of Cancer.
It is estimated that 400 million people worldwide are at higher risk of developing HCC because of cirrhosis from chronic liver diseases including chronic viral hepatitis or non-alcoholic fatty liver disease, according to a worldwide analysis of the burden of liver disease (J. Hepatology, 2019).
“Increased early detection of liver cancer could save lives, but currently available screening tests are underutilized and miss many cancers,” says Victor Velculescu, M.D., Ph.D., professor of oncology and co-director of the Cancer Genetics and Epigenetics Program at the Johns Hopkins Kimmel Cancer Center, who co-led the study with Zachariah Foda, M.D., Ph.D., gastroenterology fellow, Akshaya Annapragada, M.D./Ph.D. student, and Amy Kim, M.D., assistant professor of medicine at the Johns Hopkins University School of Medicine.
Of the 724 plasma samples studied, 501 were collected in the U.S. and E.U. and included samples from 75 people with HCC to train and validate the machine learning model, a type of artificial intelligence that uses data and algorithms to improve accuracy, explains Foda. For validation, an additional 223 plasma samples were analyzed from individuals in Hong Kong and included samples from 90 people with HCC, 66 with hepatitis B virus (HBV), 35 with HBV-related liver cirrhosis and 32 people with no underlying risk factors.
The DELFI technology uses a blood test to measure the way DNA is packaged inside the nucleus of a cell by studying the size and amount of cell-free DNA present in the circulation from different regions across the genome. Healthy cells package DNA like a well-organized suitcase, in which different regions of the genome are placed carefully in various compartments. The nuclei of cancer cells, by contrast, are like more disorganized suitcases, with items from across the genome thrown in haphazardly. When cancer cells die, they release DNA fragments in a chaotic manner into the bloodstream.
DELFI identifies the presence of cancer by examining millions of cfDNA fragments for abnormal patterns, including the size and amount of DNA in different genomic regions. The DELFI approach only requires low-coverage sequencing, enabling this technology to be cost-effective in a screening setting, the researchers say.
In the latest study, researchers performed the test — which was previously shown to accurately classify lung cancer — on cfDNA fragments isolated from the plasma samples. They analyzed the patterns of fragmentation across each sample to develop a DELFI score.
Scores were low for cancer-free individuals with viral hepatitis or cirrhosis (median DELFI score was 0.078 and 0.080, respectively), but, on average, 5 to 10 times higher for the 75 HCC patients in the U.S./E.U. samples, with high scores observed across all cancer stages, including early-stage disease (DELFI scores for Stage 0 = 0.46, Stage A = 0.61, Stage B = 0.83, and Stage C = 0.92). In addition, the test detected fragmentation changes in the content and packaging of liver cancer genomes, including from genome regions associated with liver-specific activity.
The DELFI technology detected liver cancers at their earliest stages, with an overall sensitivity — or ability to accurately detect a cancer — of 88% and a specificity of 98%, which means it almost never incorrectly provided a false positive result, among people at average risk. In samples collected from those at high risk of HCC, the test had 85% sensitivity and 80% specificity.
“Currently, less than 20% of the high-risk population get screened for liver cancer due to accessibility and suboptimal test performance. This new blood test can double the number of liver cancer cases detected, compared to the standard blood test available, and increase early cancer detection,” says Kim, co-senior author on the study.
The researchers say next steps include validating this approach in larger studies for clinical use.
More than 800,000 people are diagnosed with liver cancer worldwide each year, and it is a leading cause of cancer deaths worldwide, according to the American Cancer Society.
In addition to Velculescu, Foda, Annapragada and Kim, other researchers were Kavya Boyapati, Daniel Bruhm, Nicholas Vulpescu, Jamie Medina, Dimitrios Mathios, Stephen Cristiano, Noushin Niknafs, Harry Luu, Michael Goggins, Robert Anders, Jing Sun, Shruti Meta, David Thomas, Gregory Kirk, Vilmos Adleff, Jillian Phallen and Robert Scharpf.
The research was supported by the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, Stand Up to Cancer-Dutch Cancer Society International Translational Cancer Research Dream Team Grant (SU2C-AACR-DT1415), the Gray Foundation, the Commonwealth Foundation, SU2C INTIME Lung Cancer Interception Dream Team Grant, the Mark Foundation for Cancer Research, a research grant from Delfi Diagnostics, the National Institutes of Health grants CA121113, CA006973, CA233259, GM136577, CA237624 and CA062924, and Department of Defense CDMRP Award W81XWH-20-1-0605. Stand Up to Cancer is a program of the Entertainment Industry Foundation administered by the American Association for Cancer Research.
The researchers disclose the following competing interests: Velculescu is a founder of Delfi Diagnostics, serves on the board of directors and as a consultant for this organization, and owns Delfi Diagnostics stock, which is subject to certain restrictions under Johns Hopkins University policy. Additionally, The Johns Hopkins University owns equity in Delfi Diagnostics. Velculescu divested his equity in Personal Genome Diagnostics (PGDx) to LabCorp in February 2022. He is an inventor on patent applications submitted by The Johns Hopkins University related to cancer genomic analyses and cell-free DNA for cancer detection that have been licensed to one or more entities, including Delfi Diagnostics, LabCorp, Qiagen, Sysmex, Agios, Genzyme, Esoterix, Ventana and ManaT Bio. Under the terms of these license agreements, the university and inventors are entitled to fees and royalty distributions. Velculescu is an adviser to Danaher, Takeda Pharmaceuticals and Viron Therapeutics. Scharpf is a founder and consultant of Delfi Diagnostics and owns Delfi Diagnostics stock subject to certain restrictions under university policy. These arrangements have been reviewed and approved by The Johns Hopkins University in accordance with its conflict-of-interest policies.
Journal
Cancer Discovery
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.